Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Enhertu granted BTD for HER2-low breast cancer

27 April 2022 07:00 BST Enhertu granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer Based on DESTINY-Breast04 results where AstraZeneca and Daiichi Sankyo's Enhertu demonstrated a significant improvement in both progression-free survival and overall survival Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US

Alimak Group: Interim report January – March 2022

Focus on profitable growth · Continued profit improvement driven by revenue growth and improved gross margin · Continued strong order growth in Services · Organic revenue growth of 3% for the Group despite impacts from exiting of tower internals · Full speed to execute on phase three of the New Heights Programme, profitable growthFirst quarter 2022 · Order intake decreased by 2% to MSEK 1,053 (1,073) with an organic decrease of 9% · Service order intake increased 7% organically excluding Rental · Revenue increased by 11% to MSEK 936 (846) with an organic increase of

Interim report for first quarter 2022

A broader and stronger licensing business strengthens our position in infection preventionFirst quarter (January-March 2022) · Revenues amounted to SEK 55.2 (41.8) million, an increase of 32%, mainly through higher licensing revenues. Adjusted for currency the increase was 23%. · EBITDA amounted to SEK -4.0 (1.9) million with an EBITDA-margin of -7% (5%), a result of initiated investments in accordance with the focused growth strategy. · Operating profit amounted to SEK -16.6 (-9.7) million. · Net loss for the period amounted to SEK -16.5 (-10.5) million. Earnings per share

Alligator Bioscience AB: Interim report January–March 2022

A Quarter of Advancements for Alligator’s Key Assets “Q1 2022 was marked by many important advancements. We made progress with our key assets, mitazalimab and ATOR-1017, and ATOR-4066 and welcomed a new Chief Medical Officer to strengthen our medical leadership.” Søren Bregenholt, CEO Alligator Bioscience AB SIGNIFICANT EVENTS JANUARY-MARCH Pipeline: · In March, the Company successfully completed the Phase Ib part of the clinical study OPTIMIZE-1, and Phase II is now enrolling patients at the recommended dose of 900 µg/kg. · In January, Alligator initiated a sponsored

Quarterly Report Q1 2022

A strong start to the yearFirst quarter · Net sales increased by 22% to SEK 26,591 M (21,805), with organic growth of 14% (4) and acquired net growth of 0% (4) · Very strong organic sales growth in Americas, Entrance Systems and Global Technologies and strong growth in EMEIA, while organic sales declined in Asia Pacific · Three acquisitions with combined annual sales of about SEK 250 M were signed in the quarter · Operating income (EBIT) was SEK 4,001 M (3,187), corresponding to an operating margin of 15.0% (14.6) · Net income[ ]amounted to SEK 2,859 M (2,253) · Earnings

Modeling published in Neurology and Therapy suggests that lecanemab could delay progression to Alzheimer's dementia by several years

Stockholm, April 27, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that an article about long-term health outcomes of the investigational anti-amyloid-beta (Aβ) protofibril antibody lecanemab (BAN2401) in people living with early Alzheimer’s disease (AD), using disease modeling, was published in the peer-reviewed journal Neurology and Therapy. In this simulation, lecanemab treatment is estimated to slow the rate of disease progression, maintaining treated patients for a longer duration in earlier stages of the disease.The article focuses on the long-

Peafowl Plasmonics raises 40 MSEK to bring transparent solar power to the market

Peafowl Plasmonics takes the next step on their commercialization journey. With this seed round of funding, co-led by Industrifonden and Navigare Ventures, and backed by current owners, the company is disrupting energy supply with transparent solar power to replace batteries and cables, making our world greener, smarter, and more sustainable.The necessity to reduce energy consumption and the ever-increasing demand for renewable energy sources are driving the development of new technology. Peafowl’s direct plasmonic light harvesting cell converts light into electricity, using plasmonic

Interim Report January – March 2022

· Net sales totaled SEK 32,574 (15,723) thousand, with a growth rate of 107%. About SEK 10 million relates to the license agreement in 2021 with Selecta Biosciences. Growth is 91%, adjusted for currency effects. · Gross profit rose by 96% to SEK 29,419 (15,017) thousand. · Operating profit before depreciation and amortization (EBITDA) totaled SEK 11,717 (1,958) thousand. · Operating profit jumped SEK 9,554 thousand and totaled SEK 10,105 (551) thousand. · Comprehensive income for the period improved by SEK 11,476 thousand and totaled SEK 13,083 (1,607) thousand. · Comprehensive

Crusher economy for every business - Metso Outotec introduces renewed crusher wear offering

Metso Outotec Corporation’s press release on April 27, 2022, at 09:00 a.m. EESTMetso Outotec is introducing its renewed crusher wears solution offering catering the industry’s widest variety of wear parts and services enabling customers’ sustainable, predictable, and profitable crushing. The portfolio is categorized to three different product ranges – Metso Outotec O-Series, Expert Series and Max Series. The renewed crusher wears and services offering, from seasonal crushing to high-volume, and high-value operations has been developed in response to customers’ demand for continuous

Invitation to Concentrics' presentation of the Interim Report for the first quarter 2022

Concentric's Interim Report January-March 2022, will be published on 4 May 2022, at 08.00 CET. At 10.00 CET media, investors and analysts are invited to Stockholm City Conference Center Drottninggatan 71b, Stockholm, for a presentation of the report. There will also be an opportunity to participate via telephone conference/audio cast. President & CEO Martin Kunz and CFO Marcus Whitehouse will host the presentation, which will be held in English and is followed by Q&A sessions. We look forward to your participation. See below detailed information: WEBCAST LINK 

Viaplay to show Scottish, Welsh and Northern Irish national team football in UK

· Viaplay to stream Scotland’s, Wales’ and Northern Ireland’s European Qualifiers to the FIFA World Cup 2026 and UEFA EURO 2028, UEFA Nations League 2024/25 and 2026/27 and international friendlies exclusively in UK · Over 800 National Team Football matches from across Europe, including top-ranked teams such as Belgium, Denmark, France, Germany, Italy, the Netherlands, Portugal and Spain shown exclusively on Viaplay · Viaplay to launch in UK in second half of 2022 Viaplay and UEFA have entered a four-year partnership in the UK for Viaplay to show at least 40 exclusive live matches

The shares in DNB Bank ASA will be quoted ex-dividend today

The shares in DNB Bank ASA will be quoted ex-dividend on 27 April 2022. A dividend of NOK 9.75 per share will be distributed on 5 May 2022 to registered shareholders as at 26 April 2022. For further information, please contact: Rune Helland, head of Investor Relations, tel: +47 977 13 250 This information is subject to the disclosure requirements according to Section 5-12 of the Norwegian Securities Trading Act.

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2021

GOTHENBURG, Sweden, April 27, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced that the company's annual report and corporate governance report for the financial year 2021 are now available on the company's website, www.isofolmedical.com .For further information, please contact Isofol Medical AB (publ)Jarl Ulf Jungnelius, M.D., Chief Executive Officer  E-mail: jungnelius@isofolmedical.com  Phone: +46 (0) 709 16 89 55   Gustaf Albèrt, CFO and deputy CEOE-mail: gustaf.albert@isofolmedical.com

Changes in Handelsbanken’s executive management

Monika Bergström has been appointed Chief Compliance Officer at Handelsbanken and will be co-opted to Handelsbanken’s Group executive management. Monika Bergström is currently acting Head of Group Compliance and was previously the deputy head. “I am delighted to welcome Monika Bergström as Chief Compliance Officer at Handelsbanken. An obvious appointment, given Monika’s long-time experience in the Bank and extensive knowledge of compliance”, says Carina Åkerström, President and Group Chief Executive Officer at Handelsbanken. ”I am very pleased to be entrusted with the role of Chief

Finnair Group Interim Report 1 January – 31 March 2022

Finnair Plc                  Interim Report                 27 April 2022 at 9.00 a.m. EEST Recovery from the pandemic progresses at pace whilst we are adapting to the reality of the closed Russian airspace   January – March 2022 · Earnings per share were -0.15 euros (-0.11)*. · Revenue increased by 252.1% to 399.8 million euros (113.6). · Comparable operating result was -132.9 million euros (-143.2). Operating result was -164.9 million euros (-149.1). · Cash funds were 1,136.5 million euros (31 Dec 2021: 1 265.7) and the equity ratio was 7.2 per cent (31 Dec 2021: 11.8).

Hybrid loan granted by the State of Finland to Finnair converted to capital loan

Finnair Plc                  Stock Exchange Release                 27 April 2022 at 9.00 a.m. EEST  Finnair and the State of Finland signed an agreement on a hybrid loan of maximum 400 million euros to support Finnair due to the COVID-19 pandemic in March 2021. The arrangement has the approval of the EU Commission’s competition authority in line with the European Union’s state aid rules and, therefore, the entire amount of 400 million euros is available for Finnair to use. In its meeting on 19 April 2022, the Ministerial Committee on Economic Policy supported the conversion of the

Electrolux Professional AB interim report Q1 2022

First quarter, January–March 2022· Net sales amounted to SEK 2,484m (1,661). Sales increased by 49.6%. Organically sales increased by 25.5%. The acquisition of Unified Brands contributed with 19.9%. · EBITA amounted to SEK 236m (103), corresponding to a margin of 9.5% (6.2). EBITA includes Unified Brands integration related costs of SEK –15m. · Operating income amounted to SEK 199m (88), corresponding to a margin of 8.0% (5.3). · Operating cash flow after investments amounted to SEK –42m (23). · Income for the period amounted to SEK 155m (55), and earnings per share was SEK 0.54

Orexo´s partner Gesynta Pharma granted Orphan Drug Designation by the FDA for OX-MPI (GS-248) for the treatment of systemic sclerosis

Uppsala, Sweden – April 27, 2022 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announces today that the company´s partner Gesynta Pharma AB which owns all the rights to OX-MPI (GS248), a drug candidate for the treatment of systemic sclerosis, has been granted Orphan Drug Designation in the US by the Food and Drug Administration (FDA).   Systemic sclerosis (also known as scleroderma) is a chronic, autoimmune disease that affects, among other things, the body's smallest vessels, the microvasculature, and is associated with great medical needs due to the current lack of safe and effective

SBB, Interim Report January – March 2022: Strong profit from property management

SAMHÄLLSBYGGNADSBOLAGET I NORDEN AB (PUBL): INTERIM REPORT JANUARY - MARCH 2022 IN BRIEF: The quarter in brief · Rental income increased with 38 percent to SEK 1,831m (1,325). · The operating surplus increased with 34 percent to SEK 1,153m (858). · Cash flow from operating activities before changes in working capital was SEK 738m (389). · Profit from property management, adjusted for changes in value and tax from joint ventures/associated companies increased by 115 percent to SEK 1,326m (618). · Profit before tax increased to SEK 3,472m (3,117), of which: · Profit

Interim report January-March 2022

Klövern is consolidated in Corem from 15 June 2021.  • Income increased to SEK 1,099 million (258).  • Net operating income increased to SEK 727 million (184).  • Net financial items amounted to SEK –271 million (–18), of which dividends from shareholdings accounted for SEK 0 million (53).  • Profit from property management increased to SEK 409 million (157).  • Investments in new constructions, extensions and refurbishments amounted to SEK 442 million. Project development, including development of building rights, contributed with increases in value of

IRRAS AB publishes Interim Report for the period January to March 2022

Commercial Activity Normalizes, Resulting in Seventh Consecutive Quarter of Revenue Growth ” After two challenging years of pandemic-related challenges, the 1st quarter of 2022 confirmed what is possible for IRRAS moving forward.” ” Q1 2022 confirmed our organization’s clear progress, and we look forward to what lies ahead during the rest of this year. During the second quarter, our focus shifts toward completing a needed fundraising, and the process is underway to secure financing that will allow our team to build upon our recent progress for 18 months or more.” Will Martin, CEO

Detection Technology Plc business review January—March 2022

Detection Technology Plc company announcement 27 April 2022 at 09:00 (EEST) DETECTION TECHNOLOGY PLC BUSINESS REVIEW JANUARY–MARCH 2022 Detection Technology Q1 2022: Strong underlying demand, but component shortage postponed sales January–March 2022 highlights •     Net sales increased by 10.9% to EUR 20.3 million (18.3) •     Net sales of Industrial Solutions Business Unit (IBU) increased by 45.2% to EUR 3.5 (2.4) •     Net sales of Medical Business Unit (MBU) increased by 4.5% to EUR 10.5 million (10.1) •     Net sales of Security Business Unit (SBU) increased by 7.5%

YIT started several residential construction projects in January–March 2022

YIT Corporation Investor News 27 April 2022 at 9:00 a.m.YIT started several residential apartment building projects in Finland and the CEE countries in January-March 2022. The largest of the new projects in Finland and the CEE countries included As Oy Espoon Harmaaniitty, As Oy Hämeenlinnan Tempo, As Oy Helsingin Gunnel, As Oy Helsingin Berkka, As Oy Tampereen Kanavansilta, as well as the 10th phase of the Piliamiestis project in Kaunas, Lithuania, and Magnolia 2 in Bratislava, Slovakia. The total value of the aforementioned largest projects is close to EUR 130 million. The start-ups

Viking Line: Gradual normalization despite a challenging environment

Viking Line Abp                    BUSINESS REVIEW                    27.04.2022, 9.00 AM Viking Line: Gradual normalization despite a challenging environment January–March 2022 (compared to January–March 2021) · Sales amounted to EUR 58.8 M (EUR 24.6 M).  · Other operating revenue was EUR 6.0 M (EUR 10.3 M).  · Operating income totalled EUR -18.1 M (EUR -7.7 M).  · Net financial items were EUR -2.2 M (EUR -1.3 M).  · Income before taxes amounted to EUR -20.3 M (EUR -8.9 M).  · Income after taxes totalled EUR -16.2 M (EUR -7.2 M). Viking Line is not providing

There are no items matching the current filter
There are no more items matching the current filter
Back to top